The Adaptive COVID-19 Treatment Trial (ACTT)

NIH RePORTER · NIH · N01 · $25,075,500 · view on reporter.nih.gov ↗

Abstract

To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.

Key facts

NIH application ID
10330399
Project number
75N91019D00024-P00004-759102000010-1
Recipient
LEIDOS BIOMEDICAL RESEARCH, INC.
Principal Investigator
BETH BASELER
Activity code
N01
Funding institute
NIH
Fiscal year
2021
Award amount
$25,075,500
Award type
Project period
2020-04-03 → 2025-04-02